Feline diabetes mellitus (DM) is currently understood to have strong similarities to human type 2 diabetes. Veterinarians have traditionally relied upon insulin therapy to treat feline DM. However, ...

Both GLP-1 receptor agonists and SGLT2 inhibitors linked to reduced risk for ADRD, with no significant difference between them.

Older adults living with Type 2 diabetes face more than just blood sugar concerns. New research shows some of the most ...

Patients with T1D experienced greater reductions in risk for cardiovascular disease with empagliflozin compared with placebo.

Ellen Behrend, VMD, PhD, MS, DACVIM (SAIM): As far as side effects, the most common are gastrointestinal. And right now there ...

Explore medication options for kidney disease and potential side effects. Learn the best treatment options to slow ...

A new study suggests that two widely used Type 2 diabetes medications—GLP-1 receptor agonists and SGLT2 inhibitors—may help reduce the risk of Alzheimer’s disease and related dementias.

Adding Farxiga (dapagliflozin) to standard care significantly reduced the risk of death or worsening heart failure in older ...

Lori Berard, RN, DCE, Diabetes Educator, Nurse Consultant, reviews SGLT2's mechanism of action and benefits and discusses how ...

Abstracts featured at the National Kidney Foundation Spring Clinical Meeting highlighted the renoprotective benefits of SGLT2 ...

Loss of skeletal muscle mass is a known risk factor for falls. Researchers from the University of Tsukuba conducted a 5-yr follow-up study on 471 patients with type 2 diabetes and found that ...

Patients with low skeletal muscle mass are at a higher risk of falling. Certain diabetes medications, particularly SGLT2 ...